Medical News

RSS

POS website for one-stop paper shopping experience

POSPaper.com, the Internet’s premier source for point-of-sale supplies, paper products, and accessories, has expanded its website to include a “Restaurant Supplies” section as well as one-stop paper shopping for restaurants, retailers, banks, casinos, resorts, grocers, and more.

14 Sep 2009

Phase 3 results of TARGET 1 and TARGET 2 clinical trials released

Salix Pharmaceuticals, Ltd. today announced the successful outcome of two Phase 3, randomized, double-blind, placebo-controlled, multicenter trials, TARGET 1 and TARGET 2, designed to evaluate the efficacy and safety of rifaximin 550 mg TID in the treatment of patients with non-constipation irritable bowel syndrome (non-C IBS).

14 Sep 2009

IAEA's mission removing radioactive sources from Lebanon completed

An IAEA mission to get powerful radioactive sources out of Lebanon was completed 30 August 2009, after a plane carrying the high-activity cargo safely touched down in Russia, where the sources are now securely and safely stored.

14 Sep 2009

Schizophrenia: A major public health problem

Schizophrenia is a major public health problem. Affecting almost 1% of the world's population, it takes an enormous economic and social toll in addition to the distress, dysfunction, disability and mortality for those afflicted with this disease. Elements of the disease are present from birth, other aspects emerge during developmental years, and the illness becomes fully expressed in early adulthood with long-lasting implications for most patients.

14 Sep 2009

Phase IIa clinical data of EHT 0202 released

Top-line Phase IIa clinical data released today demonstrate that EHT 0202, ExonHit’s lead candidate for the treatment of Alzheimer’s disease, is safe and generally well tolerated in patients and that it could potentially enhance cognition in Alzheimer’s disease patients.

14 Sep 2009

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Sleep deprivation is a major factor for clinical errors

A study of clinical errors made by resident physicians in a teaching hospital reveals that the more tired they are the more mistakes they make. The study published in the International Journal of Behavioural and Healthcare Research puts figures to this seemingly obvious conclusion and shows that fewer errors are made if clinical practices are standardised.

14 Sep 2009

Eat healthy foods to prevent flu

As flu season grips the nation with heightened awareness of hand washing and cough covering, healthy eating is a potent prevention method getting left out in the cold.

14 Sep 2009

U.S. Department of Justice awards grant to Project Lifesaver International

Project Lifesaver International, a non-profit organization that helps rescue citizens who are prone to wander due to Alzheimer's disease, autism, and other cognitive disorders, received notification of federal assistance yesterday.

14 Sep 2009

National Conference on Latinos and AIDS

To educate healthcare professionals on how to improve the Latino community's access to HIV/AIDS treatment and care, Minority Health Care Communications (MHCC) will hold the National Conference on Latinos and AIDS, September 14-15th, 2009, at the New York Academy of Medicine in New York.

14 Sep 2009

Given Imaging'c PillCam COLON 2 video capsule and system receives the CE mark for sale in Europe

Given Imaging Ltd. (NASDAQ: GIVN) today announced encouraging results from a trial that validated new features of the company's second-generation PillCam® Colon video capsule and system. The Company also announced that it has obtained the CE mark for the sale of PillCam COLON 2 in Europe.

14 Sep 2009

Clinical data on CXA-101 to be presented at ICAAC

Calixa Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, will present pre-clinical and clinical data in 20 posters at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) that is being held in San Francisco on September 12 to 15, 2009.

14 Sep 2009

Innovative stroke treatment device to minimize brain damage

Driven by the emergency-room maxim, "Time is brain," NeuroInterventions, Inc. is prototyping an innovative stroke treatment device designed to speed up the restoration of blood flow and thus minimize brain damage.

14 Sep 2009

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.

14 Sep 2009

Natus Medical to purchase Alpine Biomed Holdings

Natus Medical Incorporated today announced that it has entered into an agreement to acquire Alpine Biomed Holdings Corp in a transaction that is expected to close today.

14 Sep 2009

Clinical data emphasizing on efficacy and potency of torezolid to be presented

Trius Therapeutics, Inc. announced today that 13 posters will be presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) supporting the potency, efficacy and safety of torezolid as a potential new antibiotic for the treatment of severe skin infections caused by gram positive bacteria including MRSA.

14 Sep 2009

Novant to use MEDai's Pinpoint Review patient-specific early-warning system

MEDai, Inc., an Elsevier company and leading provider of advanced solutions for healthcare that utilize award-winning predictive analytics, announced today that Novant Health, a not-for-profit integrated group of hospitals and physician practices, will roll out MEDai's Pinpoint Review(TM) to its nine hospitals in North Carolina, Virginia and South Carolina.

14 Sep 2009

Study reveals feasibility of OrbusNeich's Genous stent in patients needing undeferrable non-cardiac surgery

OrbusNeich's Genous Bio-engineered R stent is feasible and safe in patients who need coronary revascularization before undeferrable non-cardiac surgery and have to discontinue dual antiplatelet therapy, according to a paper published online in the International Journal of Cardiology (Int J Cardiol. 2009 Aug 21. [Epub ahead of print]).

14 Sep 2009

Somatic Systems files financial reports with Pink Sheets

Somatic Systems, Inc. (PINKSHEETS: SMAS) announced that it has released its most recent financial reports, bringing its financial reporting status current on Pink Sheets.

14 Sep 2009

Phase III clinical trial results of DAR-31 published

Gilead Sciences, Inc. today announced the publication of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve blood pressure goal while adhering to full doses of an appropriate three (or more) drug antihypertensive regimen that includes a diuretic.

14 Sep 2009